Revive says DRDC study finds bucillamine preserves GABA receptor signaling in nerve-agent animal model

• Revive reported positive results from a DRDC study testing bucillamine in an established animal model of nerve-agent exposure.
• Bucillamine preserved hippocampal GABA receptor post-synaptic density versus controls, matching N-acetylcysteine on that endpoint.
• No pulmonary hemorrhage appeared in the bucillamine group, while it was observed in the N-acetylcysteine group.
• Seizure activity and other clinical effects were similar across all study groups.
• DRDC plans confirmatory studies starting in Q4 2026 to assess brain injury, oxidative stress, standard-treatment response, respiratory function.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revive Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608120755ACCESSWRNAPR_____1206464) on August 12, 2026, and is solely responsible for the information contained therein.